Find biotech & pharma buyers already qualified to your ICP.
870K+ verified contacts across biotech research and pharmaceutical manufacturing - bench scientists to VPs of R&D, clinical ops, and procurement. Ken qualifies each company against your ICP with AI, writes the email from real prospect data, and lands it in the inbox.
Example searches
- VPs of R&D at clinical-stage biotech companies with 200-1,000 employees
- Heads of Clinical Operations at pharma companies with 200-1,000 employees running active trials
- Lab Directors at biotech companies running an active Phase 2 trial
- Procurement leads at pharmaceutical manufacturers with 500+ employees
Trusted by 1,000+ B2B companies
- SaaSRise
870K+ life-sciences contacts. Generic pitches get deleted.
Biotech and pharma buyers get pitched by every lab-equipment, CRO, and software vendor in the category, and a generic outreach email reads as noise instantly. A title alone - VP of R&D, Clinical Ops - says nothing about trial stage or company focus, and static contact lists can't tell you which ones actually fit. Ken qualifies each company against your ICP with AI that reads its website and public filings, on top of 870K+ biotech and pharma contacts, then personalizes each email from the prospect's actual trial phase, publication history, or role.
- biotech & pharma contacts
- 870K+
- research, clinical, and manufacturing roles across 10+ source platforms
- verification rounds per email
- 3x
- 65% of risky or invalid addresses filtered before you send
- company profiles
- 24M
- including biotechs too new or too small for standard databases
- free credits to start
- 1,000
- no card; about 690 finished leads
Signals Ken actually acts on.
Not guesswork. Real engagement from real prospects, plus fit scored before the email sends.
Multi-click intent on pipeline overviews and trial pages
A scientist or procurement lead who clicks your trial-data or product link more than once is showing real intent. Ken flags it and can fire the next touch automatically or route them straight to you.
Re-engage quiet life-science buyers
A lab director who engaged and then went quiet gets picked back up automatically. Ken watches for clicks that stop and re-approaches with a different angle before the thread goes cold.
Sort biotech & pharma replies the moment they land
Every reply from a researcher or clinical lead is classified the moment it lands - interested, not interested, or out of office - and routed or handled automatically, so real conversations reach you and the noise does not.
Qualified to your trial stage
Score every company against criteria a directory cannot express - “clinical-stage biotech with an active Phase 2 trial” or “pharma manufacturer expanding a production line.” Ken reads each site and public filings so under-fit accounts never enter the sequence.
Built for a market that moves on trial timelines.
Filter on trial stage, not just job title.
“Clinical-stage biotech with an active Phase 2 trial” or “pharma manufacturer expanding a production line.” Ken's AI reads each company's site and public filings to score it against your actual ICP.
Emails that reference the actual science.
Scientists and clinical leaders ignore generic pitches instantly. Ken writes from real prospect data - recent publications, trial updates, and role - inside human-written frameworks. In our 500k-email study, this lifted engagement 127% while generic AI dropped it 25%.
Researchers move between labs fast.
Scientists and clinical staff rotate between academia, biotech, and pharma constantly, and a stale list burns your sender reputation. Ken verifies every address three times, filtering out 65% of risky or invalid emails before you send.
From ICP to booked meetings.
Three steps. Nothing sends until you approve.
Describe your buyer
Paste your website and Ken drafts your ICP and offer - or describe it yourself: trial stage, company size, role, qualification criteria. Edit and confirm in under a minute.
Review your campaign
Ken sources biotech and pharma leads, qualifies each against your criteria, segments them, and drafts personalized multichannel sequences in your voice. Nothing sends until you approve it in your queue.
Send and take the meetings
Approve and launch from your own inboxes, or from Ken inboxes on Ken AI. Replies get sentiment-tagged, positives reach you instantly, and meetings land on your calendar.
Frequently Asked Questions
What teams ask before running outbound for Biotech & Pharma with Ken.
Ken Search covers 870K+ contacts across biotechnology research and pharmaceutical manufacturing - inside Ken's database of 250M people and 24M companies. You can slice them by function, seniority, company size, location, and AI-qualified fit to your ICP.
Yes. Filter by standard firmographics - company size, location, function - and layer in subjective AI criteria like “clinical-stage biotech with an active Phase 2 trial” or “pharma manufacturer expanding a production line.” Ken's AI reads each company's website and public filings to qualify it against exactly that.
A database export is step one of nine. Ken runs the whole engine: sourcing against your ICP, triple email verification, AI qualification, segmentation, copywriting, personalization, sending on managed infrastructure, reply handling, and analytics. You approve the campaign; Ken does the grunt work.
It works when the fit and specificity are both right. Ken qualifies every lead against your ICP with AI, then personalizes each email from the prospect's own trial data, publications, or role. That combination produced 127% higher engagement than unpersonalized copy in our 500k-email study, and 7x more meetings per 10k contacts than the industry average.
Start free with 1,000 credits. No card. Ken AI is $200/mo with 200,000 sends a month. Or have our team run it for you and pay per held meeting.
870K+ life-sciences contacts, already qualified to fit.
Build a campaign on your exact biotech or pharma ICP. Get early access or book a call. Campaigns are sourced, verified, qualified, and written. Send when you like what you see.
